Leukaemic expression of anaplastic large cell lymphoma with 46,XX,ins(2;5)(p23;q15q35) in a child with dihydropyrimidine dehydrogenase deficiency TO 
THE EDITOR
In the Revised European-American Classification of Lymphoid Neoplasms (REAL) anaplastic large cell lymphoma (ALCL) is defined as subtype of peripheral T cell and NK cell neoplasms. In concert with a characteristic morphological spectrum, tumour cells always express CD30 and often EMA. The expression of CD45, CD25 and T cellassociated antigens including CD3 is variable. Expression of CD15 is seldomly found. Classical cytogenetic analysis has shown a unique translocation involving bands 2p23 and 5q35. As a result a fusion gene of nucleophosmin (NPM: located at 5q35) and anaplastic lymphoma kinase (ALK; located at 2p23) comes to expression.
1 Clinically the tumour occurs at all ages, but is rare in very young children, but there is a peak incidence in adolescence.
2 ALCL involves mostly single or adjacent lymph nodes in peripheral regions. In adults bone marrow involvement has been described in a few cases. 3 Leukaemic presentation (ie malignant cells present in the peripheral blood) has not been noted in ALCL. 4 It is stated that in children with ALCL expressing t(2;5) only nodal tumours are noted. 5 Recently, we diagnosed a form of t(2;5) in conjunction with leukaemic presentation with bone marrow involvement in a child with ALCL. Generalised involvement of only very small sized lymph nodes, which were clinically more compatible with a viral infection, was noted.
The previously healthy 6-year-old girl from non-related Caucasian parents was admitted to our department for anaemia and progressive enlargement of liver and spleen. In the referring hospital these anomalies had been observed for 4 weeks. No malignant cells were seen in the peripheral blood. Initially a non-malignant disease had been suspected. On admission, massive enlargement of the liver (7 cm below the costal margin) and spleen (8 cm), small skin papules (diameter 4 mm), small lymph nodes (diameter 1 cm) in the neck, both axillae and in both inguinal regions and hypertrophy of tonsils and adenoid were present. At presentation blood examination revealed: leucocytes 34 × 10 9 /l, platelets 16 × 10 9 /l and on differential count 12% blasts. Biopsy of several of the small lymph nodes showed an anaplastic large cell lymphoma 'small cell variant', bone marrow aspiration showed 11% malignant cells. The malignant cells were CD30, CD4, CD2, CD7, CD45, HLA-Dr, granzymeB and ALK1 positive. CD3, CD5, CD8, CD14, CD15, CD20, CD10, CD19, CD22 were negative. A 46,XX,ins(2;5)(p23;q15q35) and a rearrangement of the J-␤-2-gene of the T cell receptor were found. Abdominal ultrasound examination did not reveal lymph nodes. Chest X-ray, CT scanning of the brain and cerebrospinal fluid were normal. Biopsy of the skin lesions only showed accumulation of neutrophils. Since the differential diagnosis at admission was not confined to a malignant disease metabolic screening was also done. Prior to the start of the chemotherapy, on urinary analysis excretion of uracil (1046 mol/mmol creatinine), thymine (497 mmol/mmol creatinine) and 5-hydroxymethyluracil (173 mol/mmol creatinine) was found. Later on, no dihydropyrimidine dehydrogenase (DPD) could be detected in bone marrow cells collected at a moment where malignant cells were not seen in the aspiration. Induction therapy (dexamethasone, vincristine, mitoxantrone and L-asparaginase) was started. The hypertrophy of lymphatic structures in the upper respiratory tract disappeared and liver and spleen enlargement decreased. Complete remission was not documented. After 6 weeks mental deterioration, paresis of legs and arms and incontinence was noted. Lumbar puncture was not informative due to gross blood contamination. Multiple cerebral and spinal lesions and meningeal infiltrations were noted on CT scanning. Spinal irradiation (6 Gy) was given to relieve symptoms. Prolonged treatment with etoposide and cytosin-arabinoside was started. Six months after initial presentation the patient died from pneumonia and septicemia caused by Klebsiella pneumoniae. At autopsy small scars around cerebral vessels and in the leptomeningeal structures were noted. No vital tumour cells were noted. Lymph nodes, bone marrow, thymus, spleen and liver did not show malignant cells.
Anaplastic large cell lymphoma (ALCL) is not a common lymphoma in childhood. The report of Ló pez-Guillermo et al 4 mentions that 20 out of 30 patients were above the age of 60. However ALCL expressing the ALK1 protein is more frequent at a younger age. Sixty percent of ALK1 positive patients are children.
2 But only 19% of ALK1 positive cases are under the age of 10 years. 3 In our case several findings are uncommon, ie the histologic subtype 'small-cell variant', the absence of large lymph nodes, the leukaemic presentation (defined as malignant cells in the peripheral blood), the bone marrow involvement, the splenomegaly, the failure to achieve remission, the early central nervous system (CNS) involvement and the coinciding DPD-deficiency. The small-cell variant is only noted in 5% of paediatric cases. 2 Extranodal involvement is reported in 30 to 50% of cases, but ALK1 positive ALCL appears to have a very low incidence of extranodal involvement. 4 Absence of gross lymph nodes is to our knowledge very rare, but in the literature no data are reported. Although leukaemic presentation is reported in peripheral T cell lymphoma patients, this is not the case with ALCL. 4 Bone marrow involvement is seen in only 20% of ALCL cases; the majority of these patients are ALK1 positive. Liver enlargement is seen in 17% of ALK1 positive patients; but in none of the 43 ALK1-positive cases was involvement of the spleen noted. 4 Except for our earlier report on two cases CNS involvement is not reported in the literature. 6 The above-enumerated low frequent symptoms in this case of ALCL might be related to the variant of t(2;5), in which 5q15q35 was inserted at 2p23. To our knowledge this type of translocation has not yet been published.
In children, deficiency of DPD is not linked with malignancies, but neurological anomalies have been reported. 7 However oncologic patients with a (partial) DPD deficiency are often detected as they suffer from severe toxicity if treated with pyrimidine-based anti-cancer drugs, such as 5-fluorouracil. 8 We did not see toxicity to another pyrimidine antimetabolite, ie cytosine arabinoside. This is not unexpected, since cytosine arabinoside is not degraded by DPD. Whether DPD deficiency is related to abnormal symptomatology and the nonachievement of remission (which is achieved in most cases of ALK1-positive ALCL) remains speculative. 3, 4 The most important conclusions from our patient, which are in contrast to other reports, are the observations that leukaemic presentation does occur in ALK1 positive ALCL patients and that ALK1 expression is not only limited to nodal tumours. + early hematopoietic precursors. A second MAB, AC141, has become available which recognizes the same antigen as AC133 but a different epitope. 2 Miraglia et al 2 cloned the gene and showed that this gene product was also expressed on a subset of leukemia cells. Horn et al 3 presented data on 30 patients with acute myeloid leukemia, 24 of whom expressed AC133, bright in nine and dim in 15. It was of note that dim AC133 staining was also seen on CD34 − leukemia cells in five patients. We described aberrant antigen expression on blast cells in patients with AML 4 and more recently in patients with myelodysplastic syndrome (MDS). 5 We speculated that dysregulation of antigen expression in those patients may affect the antigen recognized by MABs AC133, AC141, as well as CD34.
Bone marrow aspirates (n = 3) and peripheral blood stem cell samples (n = 13), including one preparation enriched for CD34 + precursors, were obtained from normal transplant donors. Peripheral blood samples and marrow aspirates were obtained from 14 patients with AML who were not in remission, and from 16 patients with MDS (refractory anemia (RA), RA with excess blasts (RAEB) or RAEB in transformation (RAEB-T)). Samples were processed and analyzed by multidimensional flow cytometry as described. 4 MABs used in the analysis included FITC-conjugated anti-CD34 (CD34 FITC), PerCPconjugated anti-CD45 (CD45 PerCP) (both purchased from Becton Dickinson (San José, CA, USA), and AC133PE and AC141PE (Amcell Corporation, Sunnyvale, CA, USA). A second staining step using biotin-conjugated AC133 or AC141 (Amcell Corporation) and streptavidin APC (Pharmingen, San Diego, CA, USA) was added to allow for four-color analysis.
As previously described in patients with AML, 3 AC133 was expressed on 25 of 30 samples, while CD34 was expressed on 28 of 30 marrows. Most interesting was the discordance in the intensity of expression of AC133 and AC141 in patients with AML or MDS. Precursor cells from normal marrow or peripheral blood stem cells showed a consistent staining pattern with respect to the two epitopes recognized by AC133 (bright) and AC141 (intermediate) and CD34 expression (bright) ( Figure 1A) . The relationship in the expression between these epitopes was most readily shown in four-color analysis with the gate set on blast cells (CD45 dim, decreased right angle light scatter, CD34 + ). 6 The correlation between AC133 and AC141
